Vincerx Pharma, Inc.
Vincerx Pharma, Inc.
Your view on VINC
Overview
What the company does, where it operates, and who runs it.
About Vincerx Pharma, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Raquel E. Izumi
- Headquarters
- 260 Sheridan Avenue, Palo Alto, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Raquel E. Izumi
- Headquarters
- 260 Sheridan Avenue, Palo Alto, CA, US
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer.
The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Vincerx Pharma, Inc., and the rating behind it. VINC last traded at $0.01; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Vincerx Pharma, Inc.. Starting points for Vincerx Pharma, Inc.: EPS -$5.75, beta 1.76 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Vincerx Pharma, Inc.. Vincerx Pharma, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Vincerx Pharma, Inc.. Trailing twelve-month EPS for Vincerx Pharma, Inc. stands at -$5.75. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Vincerx Pharma, Inc.. Vincerx Pharma, Inc. has reported as a listed company since 2020. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Vincerx Pharma, Inc. valued side by side against its closest peers. Vincerx Pharma, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Vincerx Pharma, Inc., and how their positions are changing. At a $52,343 market value, institutional positions materially move Vincerx Pharma, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Vincerx Pharma, Inc. executives and directors. Shares of Vincerx Pharma, Inc. have traded between $0.0010 and $10.38 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Vincerx Pharma, Inc.. Vincerx Pharma, Inc. is a $52,343 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Vincerx Pharma, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Vincerx Pharma, Inc.. Coverage tracks Vincerx Pharma, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.